Brixadi

Active Ingredient(s): Buprenorphine
FDA Approved: * May 23, 2023
Pharm Company: * BRAEBURN
Category: Opioid Dependence

Buprenorphine is an opioid used to treat opioid use disorder, acute pain, and chronic pain.[8] It can be used under the tongue (sublingual), in the cheek (buccal), by injection (intravenous and subcutaneous), as a skin patch (transdermal), or as an implant.[8][9] For opioid use disorder, it is typically started when withdrawal symptoms have begun and for the first two days of treatment under direct observation of a health-care provider.[... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Brixadi 8 mg/.16ml Subcutaneous Injection
NDC: 58284-208
Labeler:
Braeburn Inc.
Brixadi 16 mg/.32ml Subcutaneous Injection
NDC: 58284-216
Labeler:
Braeburn Inc.
Brixadi 24 mg/.48ml Subcutaneous Injection
NDC: 58284-224
Labeler:
Braeburn Inc.
Brixadi 128 mg/.36ml Subcutaneous Injection
NDC: 58284-228
Labeler:
Braeburn Inc.
Brixadi 32 mg/.64ml Subcutaneous Injection
NDC: 58284-232
Labeler:
Braeburn Inc.
Brixadi 64 mg/.18ml Subcutaneous Injection
NDC: 58284-264
Labeler:
Braeburn Inc.
Brixadi 96 mg/.27ml Subcutaneous Injection
NDC: 58284-296
Labeler:
Braeburn Inc.

Related Brands

Drugs with the same active ingredients